Oppenheimer lifts Teva price target to $52 after Weltruza approval
Oppenheimer increased its price target for Teva Pharmaceutical Industries to $52 from $50 and kept an Outperform rating. The revision follows the regulatory approval of Weltruza, Teva’s olanzapine long‑acting injectable. Oppenheimer expects a measured launch in the first half of 2027, with meaningful revenue in the second half of that year. The stock was trading around $41.6 at the time of the announcement.
Why it matters
Oppenheimer’s higher target implies roughly a 25% upside to the current price, which may attract buying interest (the firm notes a 25% upside to the new target). The launch timeline suggests revenue could begin contributing in late 2027.
Key facts
- 1Oppenheimer raised its price target for Teva to $52 from $50. marketscreener.com
- 2The stock was trading at $41.69. marketscreener.com
- 3The stock was trading at $41.57. investing.com
- 4Weltruza, an olanzapine long‑acting injectable, received regulatory clearance. investing.com
- 5Oppenheimer expects a measured launch in the first half of 2027, with meaningful revenue in the second half of 2027. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.